Breast Cancer Drug Trastuzumab Induces Cardiac Toxicity: Evaluation Of Human Epidermal Growth Factor Receptor 2 As A Potential Diagnostic And Prognostic Marker

Keywords

Breast cancer; Cardiac toxicity; HER2; Trastuzumab; Trastuzumab emtansine

Abstract

Breast cancer is one of the most prevalent forms of cancer in the United States and worldwide. Cancer occurs through the uncontrolled development of new abnormal cell growth. Clinicians and researchers strive to improve diagnostics and treatments in pursuit of remedying breast cancer, while limiting or removing any potential side effects that may arise. Unfortunately, traditional treatments, such as anthracyclines (i.e., doxorubicin), can damage the cardiovascular system. Recent strategies have utilized antibody-based compounds as singular treatments, or in conjunction with other treatments, with the aim to minimize side effects. The human epidermal growth factor receptor 2 (HER2) protein has been the target of numerous antibody-based breast cancer therapies, such as trastuzumab (TZM) and trastuzumab emtansine (T-DM1). This review will discuss the HER2 receptor as a diagnostic marker in targeting breast cancer using the therapeutic agents TZM and T-DM1, as well as discuss the induced cardiac toxicity following TZM and T-DM1 treatments.

Publication Date

1-1-2018

Publication Title

Canadian Journal of Physiology and Pharmacology

Volume

96

Issue

7

Number of Pages

647-654

Document Type

Article

Personal Identifier

scopus

DOI Link

https://doi.org/10.1139/cjpp-2018-0005

Socpus ID

85049865578 (Scopus)

Source API URL

https://api.elsevier.com/content/abstract/scopus_id/85049865578

This document is currently not available here.

Share

COinS